DMRA

Damora Therapeutics, Inc.
CAPPED RATING

Damora Therapeutics, Inc. (DMRA) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Growth (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B
Factor Score 3.4 / 5.0
Growth
D+
Factor Score 1.5 / 5.0
Profitability
D+
Factor Score 1.6 / 5.0
Momentum
C
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 14.1
EV / EBITDA -8.4
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -22.1%
Price Return 12M 387.9%
Catalyst Signal 0.00
Market Cap $1.5B
TTM Revenue N/A
Price / Sales N/A
ROE -115.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B (3.4) D+ (1.5) D+ (1.6) C (2.5) C+ (2.6) C (2.3)
2026-11-04 C+ (2.5) D+ (1.5) D+ (1.7) C (2.4) C+ (2.7) C- (2.1)
2026-10-28 C+ (2.5) D+ (1.5) D+ (1.7) C (2.4) C+ (2.7) C (2.2)
2026-10-21 C+ (2.5) D+ (1.5) D+ (1.7) C (2.3) C+ (2.6) C- (2.1)
2026-10-14 C+ (2.5) D+ (1.5) D+ (1.7) C+ (2.6) C+ (2.6) C (2.2)
Page 1 of 4